Published in J Rheumatol on June 01, 2000
[Capillaroscopy and rheumatic diseases: state of the art]. Z Rheumatol (2006) 1.13
[Capillaroscopy. Procedure and nomenclature]. Z Rheumatol (2010) 1.06
Capillaroscopy: questions and answers. Clin Rheumatol (2007) 0.84
Retinal findings in systemic sclerosis: a comparison with nailfold capillaroscopic patterns. Ann Rheum Dis (2003) 0.84
Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol (2000) 2.61
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J Rheumatol (1999) 2.08
Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis (2001) 1.95
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 1.85
Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology (Oxford) (2002) 1.82
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis (2010) 1.73
Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus (2004) 1.73
Estrogens, the immune response and autoimmunity. Clin Exp Rheumatol (1995) 1.60
Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci (1987) 1.60
Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med (2010) 1.54
Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol (2007) 1.49
Circadian rhythms in RA. Ann Rheum Dis (2003) 1.47
Involvement of the hypothalamic--pituitary--adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum (2001) 1.46
The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Prog Neuropsychopharmacol Biol Psychiatry (1997) 1.45
Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.38
Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) (2004) 1.35
Altered circadian rhythms in rheumatoid arthritis patients play a role in the disease's symptoms. Autoimmun Rev (2005) 1.28
Vitamin D and autoimmune rheumatic diseases. Rheumatology (Oxford) (2008) 1.24
Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis (2007) 1.23
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis (2010) 1.17
The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol (2005) 1.16
Macrophages, synovial tissue and rheumatoid arthritis. Clin Exp Rheumatol (1993) 1.14
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2013) 1.14
Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford) (2006) 1.14
Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat. Neuroscience (1996) 1.13
[Capillaroscopy and rheumatic diseases: state of the art]. Z Rheumatol (2006) 1.13
Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives. Semin Arthritis Rheum (1999) 1.11
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis (2009) 1.09
Sex hormone status in women suffering from rheumatoid arthritis. J Rheumatol (1986) 1.08
Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis (2006) 1.06
Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation. Clin Exp Rheumatol (2011) 1.05
Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol (2007) 1.05
Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. Ann Rheum Dis (2005) 1.04
Nailfold video-capillaroscopy in systemic sclerosis. Z Rheumatol (2004) 1.02
Melatonin serum levels in rheumatoid arthritis. Ann N Y Acad Sci (2002) 1.02
Characterization of synovial fluid fibronectin from patients with rheumatic inflammatory diseases and healthy subjects. Arthritis Rheum (1984) 1.01
The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) (2000) 1.00
Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology (Oxford) (2000) 1.00
Vitamin D involvement in rheumatoid arthritis and systemic lupus erythaematosus. Ann Rheum Dis (2009) 1.00
Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. J Clin Endocrinol Metab (1996) 0.99
Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease. Clin Exp Rheumatol (2001) 0.98
Plasma glucose concentration in symptomatic osteoarthritis: a clinical and epidemiological survey. Clin Exp Rheumatol (1990) 0.97
No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 0.97
Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis (2003) 0.97
Gender, body mass index and rheumatoid arthritis disease activity: results from the QUEST-RA Study. Clin Exp Rheumatol (2010) 0.97
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96
The process of aging changes the interplay of the immune, endocrine and nervous systems. Mech Ageing Dev (2001) 0.95
Monoreactive and polyreactive rheumatoid factors produced by in vitro Epstein-Barr virus-transformed peripheral blood and synovial B lymphocytes from rheumatoid arthritis patients. Scand J Immunol (1990) 0.94
Sex differences in inflammation induced cartilage damage in rodents. The influence of sex steroids. J Rheumatol (1994) 0.93
A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol (2001) 0.93
Benefit of pregnancy in inflammatory arthritis. Ann Rheum Dis (2005) 0.92
Preliminary results of serum androgen level testing in men with rheumatoid arthritis. Arthritis Rheum (1984) 0.92
Neuropeptides and steroid hormones in arthritis. Curr Opin Rheumatol (1998) 0.91
Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology (Oxford) (2006) 0.91
Italian validation of the Wagnild and Young Resilience Scale: a perspective to rheumatic diseases. Clin Exp Rheumatol (2010) 0.91
Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis (2005) 0.91
Melatonin influences interleukin-12 and nitric oxide production by primary cultures of rheumatoid synovial macrophages and THP-1 cells. Ann N Y Acad Sci (1999) 0.90
Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl (2011) 0.90
Testosterone metabolism and cyclosporin A treatment in rheumatoid arthritis. Br J Rheumatol (1997) 0.90
In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. Clin Exp Rheumatol (2008) 0.89
Stress system response and rheumatoid arthritis: a multilevel approach. Rheumatology (Oxford) (1999) 0.89
Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol (2000) 0.88
Prednisone chronotherapy. Clin Exp Rheumatol (2011) 0.87
Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann N Y Acad Sci (2003) 0.87
Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients. Ann Rheum Dis (2013) 0.87
Cortisol, dehydroepiandrosterone sulfate, and androstenedione levels in patients with polymyalgia rheumatica during twelve months of glucocorticoid therapy. Ann N Y Acad Sci (2002) 0.86
Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. Baillieres Clin Rheumatol (1996) 0.86
Melatonin in rheumatoid arthritis: a disease-promoting and modulating hormone? Clin Exp Rheumatol (2003) 0.86
Comparative effects of long-term therapy with captopril and ibopamine in chronic congestive heart failure in old patients. Cardiology (1991) 0.86
Do androgens influence the pathophysiology of rheumatoid arthritis? Facts and hypotheses. J Rheumatol (1998) 0.86
The neuroendocrine immune basis of rheumatic diseases. Immunol Today (1999) 0.85
Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Rheumatology (Oxford) (1999) 0.85
Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) (2001) 0.85
Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol (2008) 0.85
Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol (2008) 0.85
The projections of the retrorubral field A8 to the hippocampal formation in the rat. Exp Brain Res (1996) 0.85